ArticleACS omega2025
Effective Components of
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in animal models of pigmentary skin disorders.Laboratory animal research · 2026Review
- Antioxidant and anti-aging activities of Salvia miltiorrhiza Bunge callus extracts in HBiogerontology · 2026Article
- The "habitat-phytochemistry-pharmacological effect" nexus: a multidimensional review of ethnomedicinalFrontiers in pharmacology · 2026Review
- Targeting Melasma: Innovations in Pigment Deposition and Photoaging in Cosmetic Dermatology.Journal of cosmetic dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe main purpose of this study was to predict and verify the active ingredients of MATERIALS AND
methods
resultsNetwork pharmacology analysis and molecular docking showed that salvianolic acid B might be the key active ingredient. In vitro cellular experiments revealed that salvianolic acid B inhibits tyrosinase activity in B16F10 cells at concentrations of 60-90 nmol/mL. In vivo animal experiments found that TYR, MDA, and TNF-α were decreased in the skin and serum of rats in the group of the low-, medium-, and high-dose groups of salvianolic acid B, and the expression of GSH-Px and SOD was increased. The high-dose groups of salvianolic acid B showed the best therapeutic effect.
conclusionIn this study, experiments collectively show that salvianolic acid B in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.